Arzeda
Arzeda designs novel proteins and enzymes using AI-driven computational methods, delivering BioSolutions for industries such as food and nutrition, home and personal care, advanced materials, and pharmaceuticals. Its products aim to improve customer products and manufacturing processes while reducing environmental impact.
Facts
- HQ
- Seattle, WA, US
- Sectors
- Biotechnology Research
- Founded
- 2009 Seattle business license
- Type
- Corporation Seattle business license
- Employees
- 79
- Registered name
- Arzeda Corp Seattle business license
- Members see funding amounts. .
- Founders
- Alexandre Zanghellini, David Baker
Is this your organization? Claim it
BP and Arzeda Expand Joint Development to Advance Commercialization of Renewable Chemical and Validate Archytas™
BP and Arzeda have entered a second-phase collaboration to accelerate commercialization of a renewable chemical important to BP, and to validate Arzeda’s Archytas™ protein design technology for improving enzymes used in bio-based production.
GeekWire profiles Arzeda’s Seattle lab highlighting its Intelligent Protein Design for brewing industrial ingredients
GeekWire profiled Arzeda’s Seattle synthetic biology lab, describing its work designing proteins to produce industrial ingredients and inviting inquiries about the company’s Intelligent Protein Design services.
Arzeda’s Protein Design Technology Featured in The Economist’s April 2019 Technology Quarterly
Arzeda, a protein design company, is highlighted in The Economist’s April 2019 Technology Quarterly on synthetic biology and invites inquiries about its Intelligent Protein Design services.
Arzeda Rises to No. 5 on Biofuels Digest’s '40 Hottest Technologies' List After BP Partnership and DOE Award
Arzeda rose to #5 on Biofuels Digest’s annual '40 Hottest Technologies in the Advanced Bioeconomy' list, up from #6 in 2017, reflecting momentum from a BP partnership, DNA-assembly collaborations, and a DOE bioproduct award. The company highlights growing interest in protein design for renewable chemicals and broader commercial applications.
Arzeda and BP Sign Joint Development Agreement to Design Enzymes Enabling BP’s Renewable Chemical Pathways
Arzeda and BP signed a joint development agreement for Arzeda to use its Archytas™ protein design software and lab capabilities to design novel enzymes that enable BP’s proprietary pathways to produce a renewable chemical with broad applications. The collaboration combines Arzeda’s computational and high-throughput protein engineering with BP’s pathway development and commercial expertise.
Arzeda licenses TeselaGen’s cloud DNA design platform to speed enzyme and pathway development
Arzeda is licensing TeselaGen’s cloud-based DNA design and biological design automation platform to accelerate its design-build-test cycle for computationally designed enzymes and metabolic pathways, aiming to improve throughput and bring products to market faster. The partnership will integrate Arzeda’s computational protein design capabilities with TeselaGen’s automated protocol generation and information-flow tools to advance microbial system engineering.
Arzeda Raises $12 Million Series A Led by OS Fund to Scale Computational Protein Design
Arzeda raised $12 million in a Series A led by OS Fund to scale its computational protein design platform, expand product development, and hire staff to increase high-throughput computing and lab screening capacity. The funding will let Arzeda serve more industrial partners and accelerate development of proteins for applications like sustainable paints, stronger plastics, and food ingredients.
Gen9 supplies Arzeda with megabase-scale synthetic DNA via MAP to speed enzyme, chemical and crop-trait development
Gen9 and Arzeda have signed a supply agreement under Gen9’s Multiplex Access Partnership to provide Arzeda with megabase quantities of synthetic DNA so Arzeda can accelerate development of enzymes, specialty chemicals, crop traits, and pharmaceutical building blocks.
Arzeda and Zymergen Sign Multi-Year Deal to Combine Archytas™/Scylax™ Design Tools with Zymergen’s High-Throughput Strain Platform
Arzeda and Zymergen signed a multi-year agreement to combine Arzeda’s computational enzyme and pathway design tools (Archytas™ and Scylax™) with Zymergen’s high-throughput strain construction platform to design, build, and test strains for producing novel molecules and materials.
Arzeda signs agreement to design enhanced SBX enzymes for Stratos Genomics to improve single-molecule DNA sequencing
Arzeda will design and engineer enhanced enzymes for Stratos Genomics’ single-molecule Sequencing by Expansion (SBX) DNA-sequencing platform using its computational protein design software to improve SBX catalyst efficiency.
People
See all 5-
Alex Zanghelini Co-founder
-
Alexandre Zanghellini Executive Officer, Director, Promoter, Co-founder and PhD — Co-Founder & Chief Executive Officer
-
Ken Barrett Executive, MBA, MS — Chief Business Officer